Renal cell carcinoma (RCC) is a common cancer, but its pancreatic metastasis is unusual. We report a case of a 50-year-old male who was under the first line of treatment for a metastatic RCC since 2009. In August 2015, he showed up to the day unit with a cholestatic jaundice, and the investigations led to the discovery of a liver function alteration and a pancreatic mass. The biopsy of the inoperable mass revealed a RCC metastasis. The localization of this metastasis complicated the management of the disease due to haemorrhage and anemia. An embolization was performed to control the local complications. The patient was commenced on everolimus but with modest results forcing us to start exclusive palliative care.
Introduction
Renal cell carcinoma (RCC) is the second most common urological malignancy, running a highly variable clinical course [1] . Among patients with RCC, 20% -30% have metastases at presentation and up to 40% -50% develop widespread metastatic disease after nephrectomy. The pancreas is an uncommon location for metastases, which accounts for less than 5% of all pancreatic malignancies [2] [3] . A variety of cancers have been shown to metastasize in the pancreas, such as colon cancer, non-small cell lung cancer, and melanoma. RCC in particular shows, besides metastases to lymph nodes, lung, liver and bones, an in- 
Case Report
A 50-year-old male (Table 1) 
Discussion
RCC is a common cancer type. When the tumor is limited and remains in stage 1, it is characterized by a high 5-year survival rate (up to 95%) [6] . However, once it develops widespread metastases, the 5-year survival rate of the patients will drop to less than 10% [7] . Pancreatic metastasis accounts for 2% -5% of pancreatic malignancies. However, it seems to be related to a relatively good prognosis and leads to a different therapy strategy [8] . Therefore, it is very important to preoperatively diagnose a pancreatic metastasis. compared a series of 7 cases to a systematic review to conclude that asymptomatic metastases and surgical procedures were independent factors associated with better survival.
In our case, the patient was non-operable and a new line of targeted therapy was the best available option.
Data suggests that RCC with pancreatic metastasis have a better outcome than lymph nodes, liver or cerebral metastasis [11] [12] . The overall survival rates are 80.6% and 72.6% at 2 and 5 years for resected patients versus 41 and 14% respectively in unresected patients [13] .
Conclusion
In conclusion, when pancreatic metastases of RCC are resectable, surgical treatment might be an option as long as no comorbidity contraindicates resection.
The optimal resection strategy involves adequate resection margins and 
